English
BCMA CHO Recombinant Cell Line (Low Expression)
BCMA CHO Recombinant Cell Line (Low Expression)
Artikelnummer
BPS79500-L
Verpackungseinheit
2 vials
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Application: Useful as BCMA-expressing target cells in co-culture assay with BCMA-CAR-T cell, for both BCMA-specific cell killing assay and cytokine production assay.
Background: B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in non-malignant tissue but almost universal expression on MM cells. CART-BCMA is an autologous T cell product engineered by lentiviral transduction to express a fully human BCMA-specific CAR (chimeric antigen receptor). CAR T cells targeting BCMA have pre-clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human BCMA protein, also known as TNFRSF17, (Genbank #NM_001192). Surface expression of BCMA was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of BCMA expression, (H. M, L), to mimic different stages of cancer target cells with various BCMA expression levels.
Genbank: NM_001192
Host Cell Line: CHO
Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Storage Stability: Store in liquid nitrogen immediately upon receipt.
Supplied As: Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
References: 1. Ghosh A, et al. CAR T cell therapy for multiple myeloma Leuk Lymphoma. 2017 Nov; 6:1-12.2. Sanchez E, et al. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn. 2018 Mar; 7:1-11.3. Sohail A., et al. Emerging immune targets for the treatment of multiple myeloma. Immunotherapy. 2018 Feb 1; 10(4):265-282.4. Sidaway P., et al. Anti-BCMA CAR T cells show promise in MM. Nat Rev Clin Oncol. 2016 Sep;13(9):530.
Application: Useful as BCMA-expressing target cells in co-culture assay with BCMA-CAR-T cell, for both BCMA-specific cell killing assay and cytokine production assay.
Background: B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in non-malignant tissue but almost universal expression on MM cells. CART-BCMA is an autologous T cell product engineered by lentiviral transduction to express a fully human BCMA-specific CAR (chimeric antigen receptor). CAR T cells targeting BCMA have pre-clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.
Description: Recombinant clonal stable CHO cell line constitutively expressing full length human BCMA protein, also known as TNFRSF17, (Genbank #NM_001192). Surface expression of BCMA was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of BCMA expression, (H. M, L), to mimic different stages of cancer target cells with various BCMA expression levels.
Genbank: NM_001192
Host Cell Line: CHO
Mycoplasma Testing: This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Storage Stability: Store in liquid nitrogen immediately upon receipt.
Supplied As: Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
References: 1. Ghosh A, et al. CAR T cell therapy for multiple myeloma Leuk Lymphoma. 2017 Nov; 6:1-12.2. Sanchez E, et al. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn. 2018 Mar; 7:1-11.3. Sohail A., et al. Emerging immune targets for the treatment of multiple myeloma. Immunotherapy. 2018 Feb 1; 10(4):265-282.4. Sidaway P., et al. Anti-BCMA CAR T cells show promise in MM. Nat Rev Clin Oncol. 2016 Sep;13(9):530.
| Artikelnummer | BPS79500-L |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 79500-L |
| Verpackungseinheit | 2 vials |
| Mengeneinheit | PAK |
| Wirt | Hamster |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
